P846Differential platelet alpha2B-adrenergic receptors gene expression levels following coronary stent implantation: the effect of Bioabsorbable Polymer Everolimus-Eluting Synergy stents

Abstract

Purpose: Alpha2B-adrenergic receptors (α2B-ARs) play a pivotal role in platelet aggregation and their blockade exerts a profound antiaggregatory effect. In this report, we evaluated alpha2B-adrenergic receptors (α2B-ARs) gene expression levels in platelets from patients with stable coronary artery disease (CAD) undergoing coronary stent implantation. Methods: Fifty nine patients with stable CAD (39 males, aged 68±16 years) who were under dual antiplatelet therapy with clopidogrel 75 mg and acetylsalicylic acid 100 mg and 20 healthy individuals (37 males, aged 69±8 years) were included. The patients underwent single vessel elective percutaneous coronary intervention and were randomized to one of three groups, for bare metal stents (BMS) or everolimus-eluting stents (EES) (n=19) or Bioabsorbable Polymer Everolimus-Eluting Synergy stents (Boston Scientific) implantation (n=22). Blood samples were obtained before, 24hours, 48 hours, and 1 month after stent implantation from which platelets were isolated. The α2B-ARs gene expression in platelets was examined by real time PCR. Results: Patients with BMS showed a significantly increased gene expression of the α2B-ARs in platelets in 1 month following stent implantation (p=0.04) while EES group revealed an increase at 48 hours (p=0.05) and returned to baseline values in 1 month (Table 1). In contrast, α2B-ARs gene expression levels in Synergy group were significantly decreased at 1 month follow up (p=0.045). (Table Presented) Conclusions: In contrast to other types of stents, Synergy stents showed a decrease in platelets α2B-ARs gene expression levels after implantation. Possibly, this type of stent offers a favorable effect in the prevention of stent thrombosis in CAD patients.